Nabriva Therapeutics PLC reports results for the quarter ended in March - Earnings Summary

Nabriva Therapeutics

05/05/2022 22:06

* Nabriva Therapeutics PLC  NBRV.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in March. The
mean expectation of two analysts for the quarter was for a loss
of 19 cents per share.
    * Revenue rose 217.1% to $8.02 million from a year ago; 
analysts
expected $9.58 million. 
    * Nabriva Therapeutics PLC's reported EPS for the quarter
was a
loss of 20 cents​.
    * The mean earnings estimate of analysts had fallen by
about 2.7%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Nabriva Therapeutics PLC shares had fallen by 27.4% this
quarter and lost 49.1% so far this year.
    * The company reported a quarterly loss of $11.82 million.
    * Wall Street's median 12-month price target for Nabriva
Therapeutics PLC is $1.68 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 5 at 09:05 p.m.  ​All
figures in US dollars unless otherwise stated